QTRX vs. LAB, CTKB, PACB, EYPT, NAUT, AKYA, FLGT, LYEL, WVE, and SIGA
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Standard BioTools (LAB), Cytek Biosciences (CTKB), Pacific Biosciences of California (PACB), EyePoint Pharmaceuticals (EYPT), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Fulgent Genetics (FLGT), Lyell Immunopharma (LYEL), Wave Life Sciences (WVE), and SIGA Technologies (SIGA). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 6.8% of Quanterix shares are owned by insiders. Comparatively, 53.1% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Quanterix and Quanterix both had 1 articles in the media. Quanterix's average media sentiment score of 0.59 beat Standard BioTools' score of 0.00 indicating that Quanterix is being referred to more favorably in the media.
Quanterix received 263 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 61.57% of users gave Quanterix an outperform vote.
Quanterix has higher revenue and earnings than Standard BioTools. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Quanterix presently has a consensus target price of $32.00, suggesting a potential upside of 105.26%. Standard BioTools has a consensus target price of $3.58, suggesting a potential upside of 51.84%. Given Quanterix's stronger consensus rating and higher possible upside, analysts clearly believe Quanterix is more favorable than Standard BioTools.
Quanterix has a net margin of -26.42% compared to Standard BioTools' net margin of -70.21%. Standard BioTools' return on equity of 0.00% beat Quanterix's return on equity.
Quanterix has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
Summary
Quanterix beats Standard BioTools on 12 of the 18 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
